Latest news with #UnitedTherapeutics
Yahoo
6 days ago
- Business
- Yahoo
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 1.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. It turns out, estimates review have trended downward during the past month. The consensus estimate has shifted -42.41% due to these changes. At this time, Corcept has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Corcept has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Corcept belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR), has gained 9.9% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. United Therapeutics reported revenues of $794.4 million in the last reported quarter, representing a year-over-year change of +17.2%. EPS of $6.63 for the same period compares with $6.17 a year ago. For the current quarter, United Therapeutics is expected to post earnings of $6.76 per share, indicating a change of +15.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.6% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for United Therapeutics. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report United Therapeutics Corporation (UTHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-05-2025
- Business
- Yahoo
Development booming for Rochester's neighbors
May 31—ROCHESTER — Just north of Pine Island on the east side of U.S. Highway 52 lies about 400 acres in the township that, if all goes well over the next year or two, should become the future economic engine of the city. In March, the city started the environmental process that would lead to the annexation of that property — now mostly farmland — with the purpose of having a developer — Minneapolis-based Ryan Companies — turn that land into an industrial and technology business park. It's a project that could bring hundreds of jobs — not counting the construction jobs — long-term to the city. How did this happen? As the old saying goes with real estate deals, it's all about location. And in this case, the booming growth of nearby Rochester is one major factor. "The proximity to Rochester is a major factor to us," said Peter Fitzgerald, vice president of real estate development for Ryan Companies. Fitzgerald listed off Pine Island's attributes. In addition to proximity to Rochester there's also a quality workforce, proximity to the Twin Cities, and quick access to major highways such as Interstate 90, Highway 52 and Intestate 35. For Fitzgerald, the idea of developing along Highway 52 between the Twin Cities and Rochester goes back to his days, oddly enough, playing for the Rochester Honkers more than 20 years ago. Back in those days, he often drove between Rochester and the Twin Cities, a drive he felt was closer and quicker than people realized. So when he began working for Ryan Companies, he remembered that drive. "Highway 52 connects the first, second and third largest cities in the state of Minnesota," he said. "It made a ton of sense to pay attention to what's happening along Highway 52." Ryan Companies has been in the development business for 85 years in Minnesota, and has worked on projects around the state. The company has many developed projects in the Twin Cities and along I-35, Fitzgerald said. So, in evaluating Pine Island he saw good infrastructure such as utilities, available land, a strong and skilled workforce, and that access to highways and three major cities. "We had nothing along Highway 52, which we thought was a miss," he said. On the north end of Stewartville, the Schumann Business Park is filling up quickly. Mayor Jimmie-John King said that's because the land is "shovel ready" for development. "When you're putting up a $100 million building — no matter how rich you think people are — people don't want to screw around for 18 months on that borrowed money," King said, referring to the estimated investment in construction by United Therapeutics, a pig-to-human transplant facility. "(United Therapeutics) figures, working with us, they'll be ready to roll a year earlier than they planned on." King said that's a big benefit to companies, having roads, sewer and water and other utilities ready to connect to a site. "That's a huge benefit to these companies that come here," he said. He pointed to Stewartville's other big deal announced this year: Amazon will build a "last mile" delivery hub in Stewartville. With the site ready to build on, he said, a company could go from signing a development deal to beginning construction in as little as 90 days. In fact, real discussions with Amazon began in January, and, if a recent week of rain hadn't occurred, he said, the company would "already be digging in the dirt." United Therapeutics and Amazon are just the latest additions to the business park, first developed in 2003, that already includes Kwik Trip, Schwickert's Construction and FedEx Ground among others. And Schumann's isn't the only area that was built to be builder-ready. Tebay's Industrial Park a few blocks to the south on Highway 63 includes manufacturers Jimmy's Salad Dressings, Halcon Furniture and Geotek Inc. All, King said, have recently expanded or have plans to expand their building footprints, and that means more jobs coming to Stewartville. Elizabeth Howard, Pine Island's city administrator, said while the Ryan Companies development is still in the early stages, site planning would indicate room for 100 to 200 jobs coming to the city. That doesn't include construction jobs for developing the site. Despite the positives of the proposed deal, Howard said she's holding back on any celebrations. Pine Island, she said, has heard it before. "I still hear it in every single meeting I go to," said Howard, referring to the never-realized Elk Run bioscience development proposed by Tower Investments in the late 2000s and early 2010s. "It's at the top of people's minds." Howard said Ryan Companies isn't Tower Investments — which is a good thing — but as this proposal works its way into the environmental review process, she's "being more hesitant that the city is dotting its I's and crossing T's with the developer." Still, there is optimism in town. In April, the city hosted a town hall meeting where the public could come and ask questions about the proposal. "It went well," said Howard. "It was positive. The crowd was mainly people living around the project, more township folks than city folks. The developer and engineer were able to answer their questions and concerns." One question has been why Pine Island? In addition to the reasons listed by Fitzgerald, Howard said the power substation on the north end of town was a plus since data centers or technology businesses are envisioned as potential tenants. Right now, Fitzgerald said, Ryan Companies isn't thinking about end users as much as it is thinking about the environmental review — which should take most of the rest of 2025 — and pre-construction issues such as permitting and zoning. "It's looking at the magnitude of this development and taking a look at what mitigations should be in place to allow for this development," he said. Once all the pre-construction work is done, then Ryan Companies will start lining up tenants for the site. Fitzgerald said all that will take time. Development of the 400-plus acres will likely take a decade in total as more businesses buy up lots within the tech park on what will become the north end of Pine Island. "You do need an anchor tenant," he said. "We'll look for that anchor tenant who will kick off that development." Ron Zeigler, CEO of Community and Economic Development Associates, the economic development arm behind many communities in Southeast Minnesota, said, "Rochester needs a strong surrounding area, and the area needs a strong Rochester." What's happening in Stewartville and Pine Island, he said, is happening to some degree in just about every community near Rochester. "Every town is doing things to make themselves ready for housing development, business development," he said. Howard said Ryan Companies first approached Pine Island about 18 months ago. After some initial inquiries, she heard nothing for a few months. "I was cautious," she said. After all, the city and it's economic development team talk to developers often. But eventually, things started to fall into place. Howard said she got the right people talking to one another: decision makers, state agencies and the city. With so many hoops to jump through for even the most motivated city and developer, as city administrator she didn't want to "put the cart before the horse." "Don't spend taxpayer dollars inappropriately," she said. That means don't get overextended on roads or utilities. Talk to the school district and keep them in the loop. Have a plan for housing. That last one can be worked on no matter what. Both Olmsted County and Goodhue County have done studies showing the need for more housing — apartments, single-family, affordable, senior housing — enough so that she's not worried about pushing too far on that front. The city is already working on quality of life issues such as parks. And Pine Island has joined with neighboring towns — Zumbrota, Goodhue and Wanamingo — to develop a regional wastewater treatment cooperative. Stewartville City Administrator Bill Schimmel said his city — just with it's two newest development announcements, Amazon and United Therapeutics — that the city is looking at somewhere between 100 and 130 new permanent jobs. That doesn't include existing businesses — Halcon, Jimmy's and Geotek — that have or will be adding new jobs. Mayor King said that even on manufacturing lines, those jobs take skills which means those are good-paying jobs. Schimmel said the city is always looking to extend current development opportunities, whether that be residential or commercial/industrial. Apartments have been built in recent years, and roughly three dozen single-family home lots are available. As for business opportunities, there's still room for Schumann's Business Park to expand, but the city is also talking to landowners — including one on the north side of Interstate 90 — for new areas of development. After all, Stewartville is something of a business hotspot. "What seems to have happened, once some of these names are on our map, there seems to be inquiries," Schimmel said. Added King: "I think what we're going to see, and we're already seeing some of it, is the secondary-type business: truck repair shops, the support network. We're starting to hear from some of those type of people. There's a lot of opportunities that way." Opening up a shop that has oil filters and other routine maintenance parts for all those Amazon trucks, he said, would be a smart plan. For Pine Island, the payoff is a little farther down the road, but Howard said she sees it coming. And, like Stewartville has discovered, success can breed more success. "I hope that this is just the tip of the iceberg," Howard said. "I hope this is our new and improved Pine Island."
Yahoo
27-05-2025
- Business
- Yahoo
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth. The 10 therapeutics stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.2%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9% since the latest earnings results. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Myriad Genetics reported revenues of $195.9 million, down 3.1% year on year. This print fell short of analysts' expectations by 2.3%. Overall, it was a softer quarter for the company with full-year revenue guidance missing analysts' expectations. 'We had a challenging first quarter of 2025 with strength in our prenatal and oncology MyRisk tests offset by softness in GeneSight and unaffected hereditary cancer tests. While we are actively working on initiatives to re-accelerate testing volumes, this will take time; therefore we are lowering our 2025 financial guidance. We are taking immediate steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth,' said Sam Raha, President and CEO, of Myriad Genetics. Unsurprisingly, the stock is down 45% since reporting and currently trades at $3.99. Read our full report on Myriad Genetics here, it's free. Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments. United Therapeutics reported revenues of $794.4 million, up 17.2% year on year, outperforming analysts' expectations by 5.6%. The business had a very strong quarter with a narrow beat of analysts' EPS estimates. However, the results were likely priced into the stock as it's traded sideways since reporting. Shares currently sit at $302.50. Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it's free. Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management. Vertex Pharmaceuticals reported revenues of $2.77 billion, up 3% year on year, falling short of analysts' expectations by 2.3%. It was a disappointing quarter as it posted a significant miss of analysts' EPS estimates. As expected, the stock is down 13.1% since the results and currently trades at $434.31. Read our full analysis of Vertex Pharmaceuticals's results here. Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. AbbVie reported revenues of $13.34 billion, up 8.4% year on year. This number beat analysts' expectations by 3.3%. Overall, it was a very strong quarter as it also logged a solid beat of analysts' constant currency revenue estimates and a decent beat of analysts' EPS estimates. The stock is up 1.5% since reporting and currently trades at $183.25. Read our full, actionable report on AbbVie here, it's free. Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children. BioMarin Pharmaceutical reported revenues of $745.1 million, up 14.8% year on year. This result topped analysts' expectations by 1%. It was a strong quarter as it also put up a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. BioMarin Pharmaceutical delivered the highest full-year guidance raise among its peers. The stock is down 8.3% since reporting and currently trades at $57.56. Read our full, actionable report on BioMarin Pharmaceutical here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
24-05-2025
- Business
- Yahoo
FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute
Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA (treprostinil) inhalation powder for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). A healthcare professional working on a computer terminal with a patient in the background. YUTREPIA, enabled by Liquidia Corporation (NASDAQ:LQDA)'s proprietary PRINT technology, is the first and only prostacyclin dry-powder formulation designed for deep-lung delivery using a low-effort, portable inhalation device. The approval is based on results from the Phase 3 INSPIRE trial, which showed YUTREPIA to be safe and well-tolerated, offering a new treatment option for over 105,000 U.S. patients suffering from PAH and PH-ILD. Liquidia Corporation (NASDAQ:LQDA)'s commercial team is preparing to launch YUTREPIA, aiming to improve exercise ability and quality of life for patients. However, United Therapeutics Corporation has filed a patent infringement lawsuit and is seeking a court order to block YUTREPIA's commercial launch, with a decision on the injunction still pending. While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Business Insider
24-05-2025
- Business
- Business Insider
Liquidia announces FDA approval of Yutrepia
Liquidia (LQDA) announced that the U.S. Food and Drug Administration has approved Yutrepia inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, to improve exercise ability. 'Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia's proprietary PRINT technology, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring less inspiratory effort,' the company stated. Dr. Roger Jeffs, Chief Executive Officer of Liquidia, said: 'Today, we celebrate for the patients and physicians who will now have access to a potential best-in-class dry-powder form of treprostinil with exceptional portability, tolerability, titratability and durability. Thank you to the clinical investigation team, our steering committee, and the members of the pulmonary hypertension patient communities who helped make this day a reality. With today's milestone, our commercial team is prepared to launch Yutrepia and bring meaningful change to the lives of patients in need, and we look forward to speaking with physicians and patients about the unique benefits of Yutrepia in the days and weeks ahead.' As previously disclosed, United Therapeutics (UTHR) filed a complaint on May 9, in the U.S. District Court for the Middle District of North Carolina against Liquidia alleging infringement of U.S. Patent No. 11,357,782 and seeks to enjoin Liquidia from commercializing Yutrepia to treat PAH and PH-ILD. United Therapeutics has filed a motion for temporary restraining order and preliminary injunction to block Liquidia from commercially launching Yutrepia. Oral argument on the motion was held on May 20. The motion remains pending with the Court.
